Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million

Core Viewpoint - Valneva SE has signed a new contract worth $32.8 million with the U.S. Department of Defense for the supply of its Japanese encephalitis vaccine, IXIARO® [1][2]. Company Overview - Valneva is a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases [6]. - The company has a strong track record of advancing multiple vaccines from early R&D to approvals and currently markets three proprietary travel vaccines [7]. - Valneva's commercial revenues support the advancement of its vaccine pipeline, which includes candidates for Lyme disease, Shigella, Zika virus, and other public health threats [8]. Product Information - IXIARO® is the only Japanese encephalitis vaccine approved by the U.S. Food and Drug Administration (FDA) and is indicated for active immunization against the disease [3][4]. - The vaccine is approved for individuals aged two months and older in various regions, including the U.S., Europe, and Canada [4]. - Japanese encephalitis is a serious infectious disease primarily found in Asia, with an estimated 70,000 cases occurring annually [5]. Contract Details - The new one-year contract allows the DoD to purchase a minimum of $32.8 million worth of IXIARO® vaccines, with the option for additional doses [2]. - Deliveries under this contract will commence immediately, continuing from a previous supply contract signed in September 2023 [2].